http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 07 May 2026 15:00:12 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html <p>Beacon Therapeutics Holdings Limited announced 12-month safety and efficacy data from its Phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa at the Association for Research in Vision and Ophthalmology Annual Meeting.</p> <p>The data showed sustained improvements in visual function measures, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry. Among participants who received a high dose, 50% achieved at least a 2-line improvement from baseline, while 25% achieved at least a 3-line improvement. For the low dose group, 67% of participants achieved at least a 2-line improvement from baseline.</p> <p>Laru-zova was generally http://www.streetinsider.com/FDA/Beacon+Therapeutics+reports+positive+12-month+data+for+XLRP+gene+therapy/26452053.html Thu, 07 May 2026 15:00:12 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html <ul type="disc"><li>Data show promising and sustained improvements across key measures of visual function, including low luminance visual acuity and mean macular sensitivity as measured by microperimetry.</li><li style="text-align:justify;">Laru-zova was generally well-tolerated through month 12, with data supporting ongoing clinical development for the treatment of patients with XLRP caused by mutations in the RPGR gene.</li><li style="text-align:justify;">Beacon remains on track to report topline data from the pivotal VISTA trial of laru-zova in the second half of 2026.<br/></li></ul> <p align="justify">LONDON and CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage http://www.streetinsider.com/Press+Releases/Beacon+Therapeutics+Announces+Positive+12-Month+Safety+and+Efficacy+Update+from+Phase+2+DAWN+Trial+of+laru-zova+in+Patients+with+X-linked+Retinitis+Pigmentosa+%28XLRP%29+at+ARVO+2026+Annual+Meeting/26452046.html Thu, 07 May 2026 15:00:00 -0400 A.06822034 A.31066700 A.50200175 A.50215197 A.50216338 A.50216347 A.60012014 O.07309882 O.14368098 O.18709770 O.20026344 O.20032830 O.22422661 O.55123966 O.55901680 SYNC